References
- McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-14
- Patrick DL, Burke LB, Powers JH,. et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007;10 (Suppl 2):S125-S137
- Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27:S217-S232
- Cines DB, Blanchette VS. Immune thrombocytopenic purpura. New Engl J Med 2002;346:995-1008
- Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al.. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-8
- McMillan R, Bussel JB, George JN,. et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83:150-4
- Zhou Q, Yang L, Chen Z,. et al. Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. Eur J Haematol 2007;78:518-23
- Mathias SD, Gao SK, Miller KL,. et al. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008;6:13
- Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. J Am Med Assoc 1995;273:59-65
- Mathias SD, Bussel JB, George JN,. et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11
- Mathias SD, Bussel JB, George JN,. et al. A disease-specific measure of health-related quality of life for use in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-62
- Anon. SF-36 physical and mental health summary scales. A manual for users of version 1.0, 2nd ed. Lincoln (RI): QualityMetric Incorporated 2001
- Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20
- Mathias SD, Gao SK, Rutstein M, et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Health Qual Life Outcomes [submitted]